Published in J Infect Dis on October 15, 2008
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS (2013) 3.36
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet (2012) 2.54
Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis (2010) 2.45
Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature (2013) 2.38
Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA (2011) 1.85
Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. J Infect Dis (2008) 1.62
Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med (2009) 1.60
A case series: herpes simplex virus as an occupational hazard. J Esthet Restor Dent (2011) 1.49
Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A (2010) 1.49
A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One (2009) 1.35
Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res (2012) 1.33
Lessons learned and unlearned in periodontal microbiology. Periodontol 2000 (2013) 1.30
HSV-2: in pursuit of a vaccine. J Clin Invest (2011) 1.29
Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol (2009) 1.24
HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa. Epidemics (2010) 1.22
Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr (2011) 1.20
The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J Infect Dis (2011) 1.19
Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. J Acquir Immune Defic Syndr (2010) 1.16
Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. Elife (2013) 1.12
The molecular basis of herpes simplex virus latency. FEMS Microbiol Rev (2012) 1.12
Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex Transm Infect (2009) 1.12
Evasion of the mucosal innate immune system by herpes simplex virus type 2. J Virol (2009) 1.05
In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease. Mol Ther Nucleic Acids (2014) 1.03
Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis (2010) 1.03
The Sordid Affair Between Human Herpesvirus and HIV. J Infect Dis (2015) 1.02
Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. J Antimicrob Chemother (2011) 1.01
Herpes simplex virus 1 microRNAs expressed abundantly during latent infection are not essential for latency in mouse trigeminal ganglia. Virology (2011) 1.01
New concepts in understanding genital herpes. Curr Infect Dis Rep (2009) 0.99
Current status and prospects for development of an HSV vaccine. Vaccine (2013) 0.98
HIV transmission: time for translational studies to bridge the gap. Sci Transl Med (2011) 0.97
Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. Antimicrob Agents Chemother (2013) 0.97
Herpes simplex virus 2 (HSV-2) prevents dendritic cell maturation, induces apoptosis, and triggers release of proinflammatory cytokines: potential links to HSV-HIV synergy. J Virol (2012) 0.95
Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med (2013) 0.95
Inhibitors of nucleotidyltransferase superfamily enzymes suppress herpes simplex virus replication. Antimicrob Agents Chemother (2014) 0.95
Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection. J Virol (2014) 0.95
An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection. J Virol (2012) 0.94
A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva. Invest Ophthalmol Vis Sci (2009) 0.94
Effects of thyroid hormone on HSV-1 gene regulation: implications in the control of viral latency and reactivation. Cell Biosci (2011) 0.94
The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention. Clin Dev Immunol (2013) 0.93
Mucosal HSV-2 Specific CD8+ T-Cells Represent Containment of Prior Viral Shedding Rather than a Correlate of Future Protection. Front Immunol (2013) 0.91
Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania. Sex Transm Infect (2011) 0.89
Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Sex Transm Dis (2010) 0.88
Synthetic α-Hydroxytropolones Inhibit Replication of Wild-Type and Acyclovir-Resistant Herpes Simplex Viruses. Antimicrob Agents Chemother (2016) 0.88
An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques. Drug Deliv Transl Res (2017) 0.86
The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines (2012) 0.85
Longitudinal study on oral shedding of herpes simplex virus 1 and varicella-zoster virus in individuals infected with HIV. J Med Virol (2013) 0.85
Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda. J Infect Dis (2015) 0.84
Increased cell-mediated immune responses in patients with recurrent herpes simplex virus type 2 meningitis. Clin Vaccine Immunol (2011) 0.84
Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding. J R Soc Interface (2014) 0.84
HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine. Viruses (2014) 0.82
Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. Int J Womens Health (2012) 0.81
Heat-induced reactivation of HSV-1 in latent mice: upregulation in the TG of CD83 and other immune response genes and their LAT-ICP0 locus. Invest Ophthalmol Vis Sci (2009) 0.81
Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa. Infect Dis Obstet Gynecol (2014) 0.81
Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides. AIDS Res Hum Retroviruses (2014) 0.80
Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin Microbiol Rev (2016) 0.80
Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults. Sex Transm Dis (2016) 0.80
Herpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons. PLoS Comput Biol (2014) 0.79
Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa. PLoS One (2016) 0.79
Virus-specific immune memory at peripheral sites of herpes simplex virus type 2 (HSV-2) infection in guinea pigs. PLoS One (2014) 0.79
Upregulation of mouse genes in HSV-1 latent TG after butyrate treatment implicates the multiple roles of the LAT-ICP0 locus. Invest Ophthalmol Vis Sci (2011) 0.78
Stability of glycoprotein gene sequences of herpes simplex virus type 2 from primary to recurrent human infection, and diversity of the sequences among patients attending an STD clinic. BMC Infect Dis (2014) 0.77
Herpes Simplex Virus Type-2 Cervicovaginal Shedding Among Women Living With HIV-1 and Receiving Antiretroviral Therapy in Burkina Faso: An 8-Year Longitudinal Study. J Infect Dis (2015) 0.76
Prospects and perspectives for development of a vaccine against herpes simplex virus infections. Expert Rev Vaccines (2014) 0.76
Viral kinetics of genital herpes: a molecular probe into host-viral interactions. J Infect Dis (2011) 0.76
Immune Escape via a Transient Gene Expression Program Enables Productive Replication of a Latent Pathogen. Cell Rep (2017) 0.75
In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation. J Infect Dis (2016) 0.75
Epidemiological impact of a genital herpes type 2 vaccine for young females. PLoS One (2012) 0.75
Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes. Sci Transl Med (2016) 0.75
State of the Globe: Detecting HSV in Clinical Setting. J Glob Infect Dis (2012) 0.75
Herpesvirus Infections and Risk of Frailty and Mortality in Older Women: Women's Health and Aging Studies. J Am Geriatr Soc (2016) 0.75
Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 0.75
Sample Size for a Binomial Proportion with Autocorrelation. Stat Commun Infect Dis (2011) 0.75
Chlamydial Pre-Infection Protects from Subsequent Herpes Simplex Virus-2 Challenge in a Murine Vaginal Super-Infection Model. PLoS One (2016) 0.75
HSV-1 as well as HSV-2 is frequent in oral mucosal lesions of children on chemotherapy. Support Care Cancer (2014) 0.75
Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents. Virology (2017) 0.75
Sexual network drivers of HIV and herpes simplex virus type 2 (HSV-2) transmission: a comparative mathematical modeling analysis. AIDS (2017) 0.75
Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA (2006) 7.46
Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis (2001) 6.35
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity (2003) 4.49
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA (2003) 4.38
Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med (1995) 4.03
Risk factors for the sexual transmission of genital herpes. Ann Intern Med (1992) 3.89
Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med (1994) 3.83
Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med (2007) 3.66
CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med (2000) 3.62
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest (1997) 3.52
Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis (2003) 3.19
Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest (1998) 2.85
Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol (2002) 2.83
Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis (2002) 2.67
Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol (2007) 2.42
Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J Infect Dis (2007) 2.33
The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis (1997) 2.31
Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest (1985) 2.28
Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A (2007) 2.13
Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. J Med Virol (2005) 1.81
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest (2002) 1.79
Latent infection with herpes simplex virus is associated with ongoing CD8+ T-cell stimulation by parenchymal cells within sensory ganglia. J Virol (2005) 1.43
Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect (2007) 1.32
Herpes simplex virus shedding among human immunodeficiency virus-negative men who have sex with men: site and frequency of shedding. J Infect Dis (1998) 1.29
Characterization of herpes simplex virus type 2 latency-associated transcription in human sacral ganglia and in cell culture. J Infect Dis (1991) 1.25
Latent virus influences the generation and maintenance of CD8+ T cell memory. J Immunol (2006) 1.22
A queueing model for chronic recurrent conditions under panel observation. Biometrics (2005) 1.18
Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2005) 1.18
Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men. J Infect Dis (2006) 1.12
Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis (2002) 1.04
Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis (2002) 0.98
Immunologic approach to herpes simplex virus. Viral Immunol (2001) 0.96
Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and Ganglia. J Virol (2007) 0.93
Detection of herpes simplex virus (HSV) in the saliva from 1,000 oral surgery outpatients by the polymerase chain reaction (PCR) and virus isolation. J Oral Pathol Med (1994) 0.89
Subtly impaired humoral immunity predisposes to frequently recurring genital herpes simplex virus type 2 infection and herpetic neuralgia. J Infect Dis (2006) 0.88
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2002) 6.99
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med (2009) 5.47
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis (2007) 4.52
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA (2003) 4.38
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA (2008) 4.19
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis (2007) 3.95
Genital herpes. Lancet (2007) 3.83
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Frequent and prolonged shedding of bocavirus in young children attending daycare. J Infect Dis (2010) 3.67
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med (2007) 3.66
Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (2011) 3.61
Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol (2004) 3.56
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42
Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. J Clin Microbiol (2006) 3.37
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis (2004) 3.23
Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis (2004) 3.23
Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis (2003) 3.19
A population-based study of primary human herpesvirus 6 infection. N Engl J Med (2005) 3.07
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis (2004) 3.01
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood (2005) 2.97
Risk factors for herpes simplex virus transmission to pregnant women: a couples study. Am J Obstet Gynecol (2005) 2.89
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine (2006) 2.89
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
Maternal and neonatal herpes simplex virus infections. N Engl J Med (2009) 2.85
Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol (2002) 2.83
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis (2008) 2.77
Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med (2012) 2.77
Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol (2002) 2.71
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis (2002) 2.67
Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol (2003) 2.64
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis (2011) 2.56
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis (2012) 2.55
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet (2012) 2.54
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood (2002) 2.48
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis (2010) 2.45
Genital herpes complicating pregnancy. Obstet Gynecol (2005) 2.45
Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis (2006) 2.43
Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol (2007) 2.42
Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood (2003) 2.41